BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
This article was originally published in The Pink Sheet Daily
Executive Summary
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.
You may also be interested in...
Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.
Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.
FDA’s Patient-Focused Meetings: Round One Selections Include Diseases Broad And Rare
Breast and lung cancer, female sexual dysfunction and hemophilia are among 16 diseases that FDA will discuss with patients to get their perspective for drug development; additional diseases will be chosen in a future round.